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There is a growing interest for connections between the central nervous system
(CNS) and systemic immune and/or inflammatory responses. The inflammatory
cytokine IL-1 has a wide spectrum of targets, which include the CNS. Intracere-
broventricular as well as systemic administration of IL-1 were reported to induce
central effects including fever (1), slow-wave sleep (2), anorexia (3), and activation
ofthe hypothalamus-pituitary axis leading to release ofadrenal corticosteroids (4,
5). Moreover, different brain cells such as astrocytes, microglia, and neurons can
respond and/or have been found to contain various cytokines like IL-1, IL-2, IL-6,
and TNF, and there is evidencethat these factors act on neuronal survival, growth,
and differentiation (1, 3, 6-10).
It is also possible that some ofthe systemic activities of IL-1 are, at least in part,
centrally mediated. In fact, early reports indicated that central administration of
crude leukocyticendogenous mediators (presumablycontaining, amongothercyto-
kines, IL-1) induced an increase of acute-phase proteins (11). The mechanism by
which centrally administered IL-1 can activate the synthesis ofhepatic acute-phase
proteins is still unknown, and the present study was aimed at revisiting this early
observation by investigating how intracerebroventricularly administered rIL-1 induced
asystemic response. Our attention was focusedon IL-6, sincethis cytokine, induced
by IL-1, plays a crucial role in the acute-phase response as a hepatocyte-stimulating
factor, and the levels of circulating IL-6 were reported to correlate with the levels
of acute-phase proteins in some infective and inflammatory diseases (12-14).
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Materials and Methods
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Male rats (250-300 g) (CD-COBS; Charles River Breeding Laboratories, Inc., Calco, Como,
Italy) were used. They were housed with free access to food and water, under a 12-h light/dark
cycle with constant temperature (21-23°C) and humidity (20-25%).
IL-1 (human rIL-1-/3; a kind gift of Sclavo, Siena, Italy) was injected either intraperitoneally,
intravenously, or intracerebroventricularly through one polyethylene cannula permanently
implanted in the lateral ventricle 3 d before the experiment (15). IL-1 was dissolved in sterile,
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pyrogen-free saline containing 0.1% BSA and administered at the dose of 200 ng/5 JAI for
each rat . Control rats were given the same volume of vehicle.
Indomethacin (Chiesi Farmaceutici, Parma, Italy) was administered at the dose of20 mg/kg,
i.p., 1 h before IL-1 .
10 d before the experiment, one group of rats was hypophysectomized according to the
procedure described by Falconi and Rossi (16) ; another group was adrenalectomized and given
1% NaCl dissolved in drinking water. For each experiment, appropriate sham-operated rats
were used as controls .
Rats were killed by decapitation, blood was collected, and serum was prepared . IL-6 in
serum samples was measured as hybridoma growth factor using the 7TD1 cell line obtained
through the courtesy ofDr. J . Van Snick, Bruxelles, Belgium, as previously described (17) .
1 U in the 7TD1 assay corresponded to 1 pg human HL-6 . The sensitivity of the assay with
rat serum was 50 U/ml .
Results and Discussion
Fig . 1 shows the effects ofintracerebroventricular administration ofIL-1(200 ng/rat)
on serum IL-6 levels at 2 h after IL-1 . The results of two different experiments are
reported, where the effect of intracerebroventricular administration was compared
with that of systemic administration (intraperitoneal or intravenous) of the same
amount of IL-1 . It is clear that centrally administered IL-1 inducedmarkedly higher
levels of IL-6 than systemically given IL-1 . The time course of IL-6 induction by
IL-1 given intravenously or intracerebroventricularly was comparable, as shown in
Fig. 2, with a peak at 2 h . When heat-inactivated (90°C, 20 min) IL-1 was injected
intracerebroventricularly, no IL-6 induction was observed (IL-6 levels were <50
U/ml), thus ruling out the possibility that endotoxin contamination of the rIL-1 prep-
aration could be responsible for the observed effect .
The higher serum IL-6 levels observedwhen IL-1 was administered intracerebroven-
tricularly rather than systemically clearly rule out the possibility that induction of
60
￿
120
￿
180
￿
24o Time (min)
FIGURE 1 .
￿
Effect ofadministration ofIL-1 (200 ng/rat) by
different routes on serum IL-6 levels . The effect of in-
tracerebroventricular administration was comparedwith that
ofintravenous or intraperitoneal administration . In these
experiments, IL-6 levels in rats injected intracerebroven-
tricularly were significantly higher (p <0.01 by student's t
test) than those ofrats where IL-1 was given intravenously
or intraperitoneally. IL-6 levels in rats given an equal volume
ofsaline (intraperitoneally, intravenously, or intracerebro-
ventricularly) were below the detection limit (<50 U/ml) .
Data represent mean ± SD of four to five rats per group.
FIGURE 2 .
￿
Time course of IL-6 in-
duction after intracerebroventricular or
intravenous administrationofIL-1 (200
ng/rat) . Data represent mean t SD of
four to five rats per group.DE SIMONI ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
1775
circulating IL-6 by intracerebroventricularly administered IL-1 might be due to a
passage of IL-1 into the circulation through the blood brain barrier.
Theeffect of IL-1 on hypothalamic thermoregulatory centersis known to be medi-
ated by prostaglandins (1, 18). It was therefore important to evaluate whether prod-
ucts ofarachidonate metabolism were involved in induction of systemic IL-6 by in-
tracerebroventricular IL-1. We have studiedtheeffect ofpretreatment with an inhibitor
of prostaglandin synthesis, indomethacin (20 mg/kg, i.p., 1 h before IL-1), which
was previously shown to inhibit the pyrogenic action of IL-1 administered in-
tracerebroventricularly (19, 20). The results reported in Fig. 3 show that indometh-
acin did not abolish the effect of centrally administered IL-1 on serum IL-6 levels.
It should be noted that indomethacin alone increased serum IL-6 levels, although
to a lesser extent than IL-1 . Maximal induction of IL-6 by indomethacin alone was
at 2 h, and was also observed with 30 mg/kg of another cyclooxygenase inhibitor,
ibuprofen(data notshown). Onepossibility for theinducing effect of cyclooxygenase
inhibitors on IL-6 levels is that prostaglandins provide an inhibitory signal for IL-6
synthesis, as it was reported for IL-1 (21).
IL-1 activates the hypothalamus-pituitary axis, causing release of pituitary hor-
mones and, ultimately, glucocorticoids (4, 5). It was therefore important to ascer-
tain whether theactivation ofthe hypothalamus-pituitary axis is responsible forthe
induction of serum IL-6 by centrally administered IL-1. For this purpose, we have
studied the induction of IL-6 in hypophysectomized rats. As shown in Fig. 4 A,
hypophysectomy did not block the induction ofIL-6 by centrally administered IL-1.
Indeed, in all the experiments, hypophysectomy increased the IL-6 response.
We have also considered the possibility that IL-6 could be released by the adrenals,
which were reported to contain high levels of IL-1 that could be released by degranu-
lation ofcatecholaminergic terminals (22). Resultsobtained usingadrenalectomized
rats are shown in Fig. 4 B. Adrenalectomy also increased the induction of IL-6 by
centrally administered IL-1. It should be pointed out that adrenalectomy, like
hypophysectomy, increased IL-6 levels even afterintraperitoneally administered IL-1
(data not shown), confirming ourprevious reports ofahigher sensitivity of adrenalec-
tomized animalsto IL-1, probably due to the absenceof feedback mechanisms mediated
by corticosteroids (23).
Taken together, these data rule out the possibility that induction of serum IL-6
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(INDO) pretreatment on IL-6 induc-
tion by intracerebroventricularly ad-
ministered IL-1 (200 ng/rat). Data rep-
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by centrally administered IL-1 is secondary to its pyrogenic action mediated by
prostaglandins or to the stimulation of the hypothalamus-pituitary axis .
The finding that intracerebroventricularadministration of IL-1 inducescirculating
IL-6 levels extends the list of central activities of IL-1 and indicates the existence
of a novel pathwaythat could explain how infections or lesions confined to the CNS
result in systemic alterations of acute-phase response parameters. The role played
by IL-1 under conditions involving disturbances in the neurotransmission has been
up to now poorly investigated. Glia cells are known to synthesize and store IL-1,
as well as other cytokines (6-10), and reactive gliosis with elevated IL-1 activity has
been recently reported afterbrain injury and in neuropathological diseases like Down's
syndrome and Alzheimer's disease (24, 25). It was also shown that elevated levels
of IL-6 are present in the cerebrospinal fluid of patients with meningitis (26), and
both IL-1 and IL-6 were found in cerebrospinal fluid of patients with HIV-1 infec-
tion of the CNS (27).
The origin of the high blood levels of IL-6 induced by intracerebroventricular
IL-1 remains to be established. IL-6 could be produced in the brain, for instance,
by microglial cells(8, 10) or endothelial cellsin the plexus chorioideus; alternatively,
via an yet undefined pathway, production could be induced at peripheral sites.
The mechanism by whichIL-1 can stimulate IL-6 production by a CNS-mediated
pathway is still unclear. Studies are in progress to investigate the brain areas and
the neurotransmitters implicated in this effect of IL-1 on the CNS and the sourceDE SIMONI ET AL.
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of the IL-6 released. Whatever the cellular origin and pathways involved, the obser-
vations reported herein provide a link whereby IL-1 produced intracerebrally or
reaching the CNS can elicit a systemic acute-phase response.
Summary
IL-1 is known to have a central role in the induction of acute-phase response, and
some ofits activities (including induction of some acute-phase proteins) were reported
to be mediated by an induction of IL-6. Administration to rats of200 ng of human
rIL-1 by intracerebroventricular injection resulted in a more marked induction of
circulating IL-6 than the same dose ofIL-1 administered systemically (intravenously
or intraperitoneally). Induction of serum IL-6 by centrally administered IL-1 was
also observed in hypophysectomized or adrenalectomized rats, suggesting that acti-
vation of the hypothalamus-pituitary-adrenal axis is not essential for this effect of
IL-1. IL-6 induction was also observed after pretreatment with indomethacin, indi-
cating that the effect was dissociated from the pyrogenic activity of IL-1. Induction
of IL-6 by a central action could represent a novel pathway in IL-1-induced acute-
phase response.
Receivedfor publication 23 January 1990.
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